France’s Transgene has impressed observers at the American Society of Clinical Oncology meeting in Chicago with promising mid-stage data on its inbestigational lung cancer vaccine.
The company said that the primary endpoint has been achieved in a Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2), which uses the Modified Vaccinia Anakara virus vector, as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer. The study involved 148 patients and was conducted in 27 centres located in France, Poland, Germany, and Hungary.
The trial met its primary endpoint, with a progression-free survival at six months of 44% (33 out of 74 patients) in the experimental arm. In the control arm, PFS at six months was 35% and the response rate is substantially higher for the combination of TG4010 with chemotherapy compared to the latter alone.
Transgene chief executive Philippe Archinard said that the results “clearly warrant pursuing development into a Phase III programme”. He added that “we will be seeking to establish a partnership in order to complete the last stages of clinical development and bring TG4010 to the market”.
